Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant, stage II-IIIB, NSCLC.

Trial Details

NCT ID

NCT06734182

Phase

PHASE2

Sponsor

Guangdong Provincial People's Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Envafolimab injections+intravenous Disitamab Vedotin+carboplatin

Locations (sample)

Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

Having sufficient understanding of this study and being willing to sign the informed consent form (ICF);
Aged 18-75 years, male or female;
Treatment-naive, histologically confirmed resectable, stage II, IIIA, IIIB (AJCC staging system, version 9) NSCLC; cTNM stage can be confirmed thro…
PET-CT or CT plus MRI should be completed before enrollment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →